N/A N=26 Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,881 Impact of Diet on Functional Gastrointestinal Symptoms
Gastrointestinal Disorder, Functional
Primary: Most Common Triggers for Food-related GI Symptoms (Top 5) — 881; 494; 469; 460 Participants
Phase 2 N=104 Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
Dyspepsia · Diabetes Mellitus With Gastrointestinal Symptoms
Primary: Mean Intestinal Chemosensitivity to Lipids Perfusion — 0.22; 0.36; 0.55; 0.65 score on a scale — p=0.06
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
N/A N=402 Multicenter Study of Patient-reported Gastrointestinal Symptoms in People With Cystic Fibrosis
Cystic Fibrosis
Primary: Number of Participants Who Fully Completed at Least One ePRO — 133; 196; 130; 194 Participants
N/A N=99 Fear, Gastrointestinal Distress, and Interoception: Physiological and Psychological Mechanisms in Eating Disorders
Feeding and Eating Disorders
Primary: Subjective Rating of Fear — -36.9444; -23.9219; -47.3611; 85.6250 units on scale*minutes — p=.879
N/A N=54 Gulf War Digestive Health Study
Irritable Bowel Syndrome · Small Intestinal Bacterial Overgrowth
Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26
N/A N=29 Dietary Triggers of Gastrointestinal Symptoms in IBS Patients
Irritable Bowel Syndrome
Primary: Number of Participants With Worsening Irritable Bowel Syndrome (IBS) Symptoms Based on IBS-SSS — 8; 10; 11 Participants
N/A N=76 Change in Gastrointestinal Complaints After Switch From Oral Parkinson's Disease Treatment to Neupro® Transdermal Patch
Idiopathic Parkinson's Disease
Primary: Change From Baseline to Visit 3 in the Assessment of Intensity of Gastrointestinal (GI) Complaints for Any Reason as Per Visual Analogue Scale (VAS) — -26.8 millimeter…
N/A N=4,561 Chronic Gastrointestinal Sequelae of an Acute Outbreak of Bacterial Gastroenteritis in Walkerton Ontario
Irritable Bowel Syndrome
Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants
N/A N=48 Evaluation of the Gastrointestinal Manifestation of Fabry's Disease
Fabry's Disease
Primary: Gastric Emptying Transit Time Measured Via SmartPill Study — 2.9; 2.8 Hours
Phase 1 N=28 To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers
Common Cold
Primary: Mean Time to Onset of Gastric Emptying — 1.107; 8.534 minutes
N/A N=110 Probiotic VSL#3 for the Treatment of Gastrointestinal Symptoms Associated to Fibromyalgia
Fibromyalgia · Gastrointestinal Disease
Primary: Change, From Baseline to Endpoint (12 Weeks) in the Composite Score of Abdominal Pain, Abdominal Bloating and Metheorism Each One Measured in a 0-10 Visual Analog Scale…
N/A N=17 Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants
Phase 4 N=237 Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
Relapsing Forms of Multiple Sclerosis
Primary: Worst Severity Score of Overall Gastrointestinal (GI) Events, Modified Overall GI Symptom Scale (MOGISS) — 4.8 units on a scale
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05
Phase 2 N=96 Buspirone for Early Satiety and Symptoms of Gastroparesis
Gastroparesis
Primary: 4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity — -1.16; -1.03 score on a scale — p=0.69
Phase 4 N=211 Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
Relapsing-Remitting Multiple Sclerosis
Primary: Number of Participants Who Utilized Symptomatic Therapy With Gastrointestinal-Related Events During the 12-Week Treatment Period: Modified Overall Gastrointestinal…
N/A N=22 Aging and Gastrointestinal Barrier Function
Aging · Hyperthermia
Primary: Log Lactulose/Rhamnose Following Control Trial — 0.97; 0.79 Ratio
N/A N=88 Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol
Gastrointestinal Diseases
Primary: Device Success Defined as the Ability to Record Myoelectric Signals in Study Subjects. — 88 participants
Phase 4 N=23 Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®
Gastrointestinal Lesions · Signs and Symptoms, Digestive
Primary: GI Mucosal Lesions Change and Clinical Symptoms Using The Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.99; 2.19 GSRS score — p=0.05
N/A N=25 Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Cystic Fibrosis
Primary: Orocaecal Transit Time — 330; 210 minutes — p=0.04
N/A N=158 Clinical Improvement and in Quality of Life-Functional Dyspepsia-
Psychogenic Dyspepsia
Primary: Change From Baseline in DYSPEPSIA RELATED HEALTH SCALE (DRHS) — 73.72; 65.31; 71.85; 64.89 units on a scale
N/A N=24 Correlates of GERD Symptom Severity
GERD
Primary: Association of Change in Patient's GSR From Beginning to End of Study Visit With GERD Symptom Severity 2 Weeks Later — -0.94; -1.70 micro-Siemens — p=0.034
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 2 N=114 A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Gastroparesis
Primary: Percentage of Responders Based on the Fullness/Early Satiety Subscale (Responders) as Assessed by Gastrointestinal Cardinal Symptom Index-Daily Diary (GCSI-DD) at Week…
Early Phase 1 N=14 Pioglitazone for Idiopathic Gastroparesis
Gastroparesis
Primary: Severity of Gastrointestinal Symptoms as Assessed by the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index — 2.9; 2.3; 2.2; 2.6…
Phase 4 N=81 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: A Change in Abdominal Pain Severity — 259.66; 256.04; 199.13; 201.98 units on a scale — p=<0.05
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 3 N=111 Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate
Autoimmune Disease
Primary: Changes in GI Symptom Severity After Conversion From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) — 2.28; 2.02; -0.28 Scores on a scale